Advertisement

Lidocaine with Epinephrine Injection

[17 July 2014]

Products Affected - Description

1% Lidocaine with epinephrine
1% Lidocaine (with epinephrine 1:100,000) injection, Hospira

10 mg/mL, 50 mL vial (NDC 00409-3178-03)
 
1% Xylocaine (with epinephrine 1:200,000) injection), Fresenius Kabi
10 mg/mL, 10 mL vial (NDC 63323-0482-17)
10 mg/mL, 20 mL vial (NDC 63323-0482-27)
10 mg/mL, 50 mL vial (NDC 63323-0482-57)
 
1% Xylocaine - MPF (with epinephrine 1:200,000 injection), Fresenius Kabi
10 mg/mL, 10 mL vial (NDC 63323-0487-17)
10 mg/mL, 30 mL vial (NDC 63323-0487-37)
 
2% Lidocaine with epinephrine
2% Xylocaine (with epinephrine 1:200,000 injection), Fresenius Kabi
20 mg/mL, 50 mL vial (NDC 63323-0483-57)
 
2% Xylocaine - MPF (with epinephrine 1:200,000 injection), Fresenius Kabi
20 mg/mL, 20 mL vial (NDC 63323-0489-27)
20 mg/mL, 20 mL vial, sterile pack (NDC 63323-0489-21)
 
2% Lidocaine (with epinephrine 1:200,000 injection), Hospira
20 mg/mL, 20 mL vial (NDC 00409-3183-01)

Reason for the Shortage

  • Hospira has lidocaine with epinephrine presentations on shortage due to manufacturing delays.
  • Fresenius Kabi (formerly APP) has Xylocaine with epinephrine presentations on shortage due to increased demand for the product.

Available Products

0.5% Lidocaine with epinephrine
0.5% Xylocaine (with epinephrine 1:200,000 injection), Fresenius Kabi (formerly APP)
5 mg/mL, 50 mL vial (NDC 63323-0481-57)
 
0.5% Lidocaine (with epinephrine 1:200,000 injection), Hospira
5 mg/mL, 50 mL vial (NDC 00409-3177-01)

1% Lidocaine with epinephrine
1% Lidocaine (with epinephrine 1:100,000) injection, Hospira
10 mg/mL, 20 mL vial (NDC 00409-3178-01)
10 mg/mL, 30 mL vial (NDC 00409-3178-02)

1% Xylocaine - MPF (with epinephrine 1:200,000 injection), Fresenius Kabi
10 mg/mL, 30 mL vial, sterile pack (NDC 63323-0487-31)


1.5% Lidocaine with epinephrine
1.5% Lidocaine (with epinephrine 1:200,000 injection), Hospira
15 mg/mL, 5 mL glass ampule, 10 count (NDC 00409-1209-01)

15 mg/mL, 30 mL vial (NDC 00409-3181-01)
 
1.5% Xylocaine - MPF (with epinephrine 1:200,000 injection), Fresenius Kabi
15 mg/mL, 10 mL vial (NDC 63323-0488-17)
15 mg/mL, 30 mL vial (NDC 63323-0488-37)
 
2% Lidocaine with epinephrine
2% Lidocaine (with epinephrine 1:100,000 injection), Hospira

20 mg/mL, 20 mL vial, (NDC 00409-3182-01)
20 mg/mL, 30 mL vial (NDC 00409-3182-02)
20 mg/mL, 50 mL vial (NDC 00409-3182-03) 
 
2% Xylocaine (with epinephrine 1:200,000 injection), Fresenius Kabi
20 mg/mL, 20 mL vial (NDC 63323-0483-27)
 
2% Xylocaine - MPF (with epinephrine 1:200,000 injection), Fresenius Kabi20 mg/mL, 10 mL vial (NDC 63323-0489-17)

Estimated Resupply Dates

0.5% Lidocaine with epinephrine

  • All presentations are currently available.

1% Lidocaine with epinephrine

  • Hospira has 1% lidocaine with epinephrine (1:100,000) 50 mL vials on back order and the company estimates a release date of July 2014.
  • Fresenius Kabi has 1% Xylocaine with epinephrine (1:200,000) 20 mL and 50 mL vials on back order and the company estimates a release date of mid-July 2014 for the 20 mL vials and mid-August 2014 for the 50 mL vials. The 1% Xylocaine with epinephrine (1:200,000) 10 mL vials are available but with short-expiration dating (<3 months).
  • Fresenius Kabi has 1% Xylocaine - MPF with epinephrine (1:200,000) 10 mL vials available but with short-expiration dating (<4 months). Additional product is expected in mid-July 2014. Fresenius Kabi has 1% Xylocaine - MPF with epinephrine (1:200,000) 30 mL vials on back order and the company estimates a release date in late-August 2014.

1.5% Lidocaine with epinephrine

  • All presentations are available.

2% Lidocaine with epinephrine

  • Fresenius Kabi has 2% Xylocaine with epinephrine (1:200,000) 50 mL vials on back order and the company estimates a release date of mid-August 2014.
  • Fresenius Kabi has 2% Xylocaine- MPF with epinephrine (1:200,000) 20 mL vials in sterile pack on available but with short-expiration dating (< 9 months). Fresenius Kabi has 2% Xylocaine- MPF with epinephrine (1:200,000) 20 mL vials on back order and the company estimates a release date in mid-July 2014.
  • Hospira has 2% lidocaine with epinephrine (1:200,000) 20 mL vials on back order and the company estimates a release date of July 2014.

Related Shortages

Updated

July 17, 2014; July 3, 2014; June 11, 2014; May 28, 2014; May 12, 2014; May 1, 2014; April 9, 2014; March 27, 2014; March 7, 2014; February 27, 2014; February 7, 2014; January 21, 2014; January 14, 2014; January 6, 2014; December 13, 2013; November 27, 2013; November 15, 2013; October 31, 2013; October 9, 2013; September 18, 2013; September 3, 2013; August 13, 2013; July 1, 2013; June 26, 2013; June 10, 2013; June 6, 2013; May 9, 2013; April 23, 2013; April 9, 2013; March 27, 2013; February 28, 2013; February 5, 2013; January 16, 2013; December 12, 2012; November 9, 2012; October 25, 2012; October 17, 2012; August 22, 2012; August 9, 2012; June 21, 2012; May 30, 2012; April 16, 2012; March 7, 2012; February 22, 2012; February 8, 2012; January 25, 2012; January 3, 2012; December 16, 2011; November 16, 2011, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement